Intriguingly, a recent report demonstrated that genetically increasing S1P levels by manipulating S1P lyase (Sply) significantly improved dystrophic muscle phenotypes in Drosophila. 39 Therefore, modulating the levels of the metabolite, S1P, or manipulating its receptor, S1PR3, by miR-127 would represent a potential therapeutic strategy for muscular dystrophy. Here, S1PR3 is linked to muscular dystrophy.